Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...
A Prescription Drug User Fee Act target date of March 6, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...
BOGOTÁ, Colombia — Most dermatologists and rheumatologists agree that GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, powerful antidiabetes and weight-loss ...
CHICAGO — Patients with psoriatic arthritis (PsA) receiving GLP-1 receptor agonists (GLP-1s) had lower risks for death and experiencing major adverse cardiac events than patients with PsA not taking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback